Ranbaxy Alleges Rivals Of Meddling With Daiichi Sankyo Deal; U.S. House Committee Enters Fray
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's leading drug maker Ranbaxy Laboratories has alleged that global big pharma players are trying to scuttle its acquisition by Daiichi Sankyo. U.S. FDA and the U.S. Department of Justice's probe of Ranbaxy is part of a larger battle against the company, CEO Malvinder Singh said in a television interview on Friday, indicating that vested interests in the global industry were trying to stall the deal